Discovering Potential Drug Targets for KYAT3 (G56267)

Target Name: KYAT3

NCBI ID: G56267

KYAT3

Discovering Potential Drug Targets for KYAT3

Kynurenine--oxoglutarate transaminase 3 (KYAT3) is a protein that is expressed in various tissues throughout the body, including the liver, heart, kidneys, and pancreas. It plays a crucial role in the metabolism of a molecule called glutathione, which is a naturally occurring antioxidant that helps protect the body against oxidative stress and damage.

KYAT3 is a member of the family of enzymes known as transferases, which are responsible for transferring a specific amino acid to another amino acid during the process of protein synthesis. In the case of KYAT3, it transfers the amino acid cysteine to the protein glutathione.

The function of KYAT3 is closely linked to the regulation of glutathione levels, as well as the detoxification of harmful substances in the body. Glutathione is a natural antioxidant that is produced by the liver and other tissues, and it has the ability to neutralize toxins and protect the body against oxidative stress.

KYAT3 is a key enzyme in the regulation of glutathione levels, as it helps to ensure that the levels of this important antioxidant are maintained in the body. It does this by catalyzing the transfer of cysteine to the protein glutathione, which helps to increase the levels of glutathione in the body.

In addition to its role in regulating glutathione levels, KYAT3 is also involved in the detoxification of harmful substances in the body. Many harmful substances, such as drugs and other toxins, can damage the liver and other tissues and cause a range of health problems if not properly detoxified. KYAT3 plays an important role in this process, as it helps to remove these harmful substances from the body.

Despite the important role that KYAT3 plays in the regulation of glutathione and the detoxification of harmful substances, it is not yet a well-established drug target or biomarker. There is ongoing research into the potential uses of KYAT3 as a drug target, with some studies suggesting that it may be a promising target for the development of new treatments for a range of diseases.

The Potential Applications of KYAT3 as a Drug Target

KYAT3 is a potentially interesting drug target due to its involvement in the regulation of glutathione and the detoxification of harmful substances. There are several potential applications for KYAT3-based therapies, including the treatment of a range of diseases.

1. Networks of Differential expression (NDEL) Analysis

Network analysis is a powerful tool that can help to identify potential drug targets by analyzing the interactions between different proteins in the body. KYAT3 has been shown to play a role in the regulation of glutathione levels and the detoxification of harmful substances, making it a potential target for drugs that are designed to modulate these processes.

One approach that has been used to identify potential drug targets based on KYAT3 is network analysis. This approach involves the use of a software tool called Cytoscape, which allows researchers to create a network of interacting proteins. By analyzing the interactions between different proteins, researchers can identify potential drug targets that are involved in the same signaling pathway.

2. Chemical Compounds

Another approach that has been used to identify potential drug targets based on KYAT3 is the use of chemical compounds. Researchers have identified a number of compounds that have been shown to interact with KYAT3 and are currently being evaluated for their potential as drug candidates.

3. Genetic Modification

Genetic modification is another approach that has been used to identify potential drug targets based on KYAT3. Researchers have used CRISPR-Cas9 technology to modify the gene expression of certain proteins and have found that these modifications can affect the activity of KYAT3. This suggests that KYAT3 may be a

Protein Name: Kynurenine Aminotransferase 3

Functions: Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA), an intermediate in the tryptophan catabolic pathway which is also a broad spectrum antagonist of the three ionotropic excitatory amino acid receptors among others. May catalyze the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond. Has transaminase activity towards L-kynurenine, tryptophan, phenylalanine, serine, cysteine, methionine, histidine, glutamine and asparagine with glyoxylate as an amino group acceptor (in vitro). Has lower activity with 2-oxoglutarate as amino group acceptor (in vitro)

The "KYAT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KYAT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets